以BRAF^(V600E)为主的分子标志物联合检测对甲状腺乳头状癌预后评估的应用价值  

Application value of BRAF^(V600E) as main molecular marker detections in the prognostic assessment of papillary thyroid carcinoma

作　　者：李婕 祝寒宇 余泽伟 许佩蓉 饶舜禹 金欣[1] LI Jie;ZHU Han-yu;YU Ze-wei;XU Pei-rong;RAO Shun-yu;JIN Xin(Medical College,Shaoxing University,Shaoxing 312000,China)

机构地区：[1]绍兴文理学院医学院,浙江绍兴312000

出　　处：《基础医学与临床》2018年第10期1470-1474,共5页Basic and Clinical Medicine

基　　金：浙江省自然科学基金公益性技术应用研究计划(LGF18H160014);浙江省大学生科技创新活动计划暨新苗人才计划(2016R428030)

摘　　要：甲状腺癌是近年来发病率上升最快的实体恶性肿瘤,其中甲状腺乳头状癌(PTC)约占90%。尽管大多数PTC预后较好,但仍有部分患者死于转移和复发。应用BRAF^(V600E)联合TERT、miRNAs及P53等分子标志物的联合检测可改善复发风险分层和预后评估,有助于更准确地识别最可能具有不良预后的PTC患者。Thyroid cancer is the malignant tumor with the most rapidly increasing incidence in recent years. Papillary thyroid carcinoma accounts for approximately 90% of thyroid cancers. Though thyroid cancer is generally associated with favorable prognosis, there are still some patients have local recurrence and distant metastasis. Molecular marker detections of BRAF V600E combined with TERT , miRNAs and P53 contribute to the prognosis and risk of recurrence, helping identify PTC patients who are most likely to have poor prognosis.

关 键 词：BRAF^V600E突变 甲状腺乳头状癌 预后 联合检测 

分 类 号：R736.1[医药卫生—肿瘤]